# Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

> **NCT04488107** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ahon Pharmaceutical Co., Ltd.** · enrollment: 78 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** FCN-437c
- **DRUG:** Letrozole 2.5mg

## Key facts

- **NCT ID:** NCT04488107
- **Lead sponsor:** Ahon Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-14
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-06-30
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2020-07-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04488107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04488107, "Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04488107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*